ACEI对2型糖尿病患者微量白蛋白尿与胰岛素抵抗的影响

目的：探讨ACE抑制剂对2型糖尿病患者微量白蛋白尿与胰岛素抵抗的影响。方法：120例2型糖尿病合并微量白蛋白与胰岛素抵抗的患者，承机分为治疗组和对照组。治疗组口服ACE抑制剂（苯那普利片）和降糖药，对照组只口服降糖药。疗程6个月。结果：ACE抑制制剂减少2型糖尿病患者尿微量白蛋白排泄（P＜0．05），显著增加患者胰岛素的敏感性（P＜0．05）。两组相比有显著差异（P＜0．05）。结论ACE抑制剂是安全有效治疗2型糖尿病微量白蛋白与胰岛素抵抗的有效药物。

ACEI in the Treatment of Microalbuminuria and Insulin ResistanceIn Patients with Type 2 Diabetes Mellitus

Objective To evaluate the clinical efficacy and safety of ACEI in the treatment of microalbuminuria and insulin resistance in patients with type 2 diabetes mellitus. Methods 120 type 2 diabetic patients with microalbuminuria and insulin resistance were divided into two groups with 60 patients each. The first group was treated with ACEI (Benazepril) and oral medicine for reducing blood glucose to compare with another group in which the patients were only received same oral medicine for reducing blood glucose for 6 months each. Results ACEI reduced microalbuminuria in patients with type 2 diabetes mellitus ( P <0.05), and also improved insulin sensitivity ( P <0.05). There was significant difference between two groups ( P <0.05). There were no adverse reactions. Conclusion ACEI is a save and effective drug for treating microalbuminuria and insulin resistance in patients with type 2 diabetes mellitus.